Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2002;40:273-279
Published online before print July 29, 2002, doi: 10.1161/01.HYP.0000029240.44253.5E
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/3/273    most recent
01.HYP.0000029240.44253.5Ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaergel, E.
Right arrow Articles by Schunck, W.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaergel, E.
Right arrow Articles by Schunck, W.-H.
Related Collections
Right arrow Animal models of human disease
Right arrow Hypertension - basic studies

(Hypertension. 2002;40:273.)
© 2002 American Heart Association, Inc.


Scientific Contributions

P450-Dependent Arachidonic Acid Metabolism and Angiotensin II–Induced Renal Damage

Eva Kaergel; Dominik N. Muller; Horst Honeck; Juergen Theuer; Erdenechimeg Shagdarsuren; Alexander Mullally; Friedrich C. Luft; Wolf-Hagen Schunck

From the Max Delbrück Center for Molecular Medicine and Franz Volhard Clinic, HELIOS Kliniken-Berlin, Medical Faculty of the Charité, Humboldt University of Berlin, Germany.

Correspondence to Wolf-Hagen Schunck, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13092 Berlin, Germany. E-mail schunck{at}mdc-berlin.de

Transgenic rats overexpressing both human renin and angiotensinogen genes (dTGR) develop hypertension, inflammation, and renal failure. We tested the hypothesis that these pathological features are associated with changes in renal P450-dependent arachidonic acid (AA) metabolism. Samples were prepared from 5- and 7-week-old dTGR and from normotensive Sprague-Dawley (SD) rats, ie, before and after the dTGR developed severe hypertension and albuminuria. At both stages, dTGR showed significantly lower renal microsomal AA epoxygenase and hydroxylase activities that reached 63% and 76% of the control values at week 7. Furthermore, the protein levels of several potential AA epoxygenases (CYP2C11, CYP2C23, and CYP2J) were significantly reduced. Immunoinhibition studies identified CYP2C23 as the major AA epoxygenase, both in dTGR and SD rats. Immunohistochemistry showed that CYP2C23 was localized in cortical and outer medullary tubules that progressively lost this enzyme from week 5 to week 7 in dTGR. CYP2C11 expression occurred only in the outer medullary tubules and was markedly reduced in dTGR compared with age-matched SD rats. These findings indicate site-specific decreases in the availability of AA epoxygenase products in the kidney of dTGR. In contrast to renal microsomes, liver microsomes of dTGR and SD rats showed no change in the expression and activity of AA epoxygenases and hydroxylases. We conclude that hypertension and end-organ damage in dTGR is associated with kidney-specific downregulation of P450-dependent AA metabolism. Because the products of AA epoxygenation have anti-inflammatory properties, this alteration may contribute to uncontrolled renal inflammation, which is a major cause of renal damage in dTGR.


Key Words: rats • kidney • cytochrome P450 • arachidonic acid • angiotensin II • inflammation • end-organ damage




This article has been cited by other articles:


Home page
HypertensionHome page
I. Fleming and R. Busse
Endothelium-Derived Epoxyeicosatrienoic Acids and Vascular Function
Hypertension, April 1, 2006; 47(4): 629 - 633.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. D. Imig
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases
Am J Physiol Renal Physiol, September 1, 2005; 289(3): F496 - F503.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. M. Seubert, F. Xu, J. P. Graves, J. B. Collins, S. O. Sieber, R. S. Paules, D. L. Kroetz, and D. C. Zeldin
Differential renal gene expression in prehypertensive and hypertensive spontaneously hypertensive rats
Am J Physiol Renal Physiol, September 1, 2005; 289(3): F552 - F561.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
X. Zhao, T. Yamamoto, J. W. Newman, I.-H. Kim, T. Watanabe, B. D. Hammock, J. Stewart, J. S. Pollock, D. M. Pollock, and J. D. Imig
Soluble Epoxide Hydrolase Inhibition Protects the Kidney from Hypertension-Induced Damage
J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1244 - 1253.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Z. Yu, B. B. Davis, C. Morisseau, B. D. Hammock, J. L. Olson, D. L. Kroetz, and R. H. Weiss
Vascular localization of soluble epoxide hydrolase in the human kidney
Am J Physiol Renal Physiol, April 1, 2004; 286(4): F720 - F726.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D. N. Muller, J. Theuer, E. Shagdarsuren, E. Kaergel, H. Honeck, J.-K. Park, M. Markovic, E. Barbosa-Sicard, R. Dechend, M. Wellner, et al.
A Peroxisome Proliferator-Activated Receptor-{alpha} Activator Induces Renal CYP2C23 Activity and Protects from Angiotensin II-Induced Renal Injury
Am. J. Pathol., February 1, 2004; 164(2): 521 - 532.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
X. Zhao, D. M. Pollock, D. C. Zeldin, and J. D. Imig
Salt-Sensitive Hypertension After Exposure to Angiotensin Is Associated With Inability to Upregulate Renal Epoxygenases
Hypertension, October 1, 2003; 42(4): 775 - 780.
[Abstract] [Full Text] [PDF]